<DOC>
	<DOCNO>NCT02326220</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group study evaluate effect alirocumab comparison placebo frequency LDL apheresis treatment patient HeFH undergo LDL apheresis therapy .</brief_summary>
	<brief_title>Study Alirocumab ( REGN727/SAR236553 ) Patients With Heterozygous Familial Hypercholesterolemia ( HeFH ) Undergoing Low-density Lipoprotein ( LDL ) Apheresis Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Men woman â‰¥18 year age time screen visit 2 . Diagnosis HeFH ( Heterozygous familial hypercholesterolemia ) 3 . Currently undergo LDL ( lowdensity lipoprotein ) apheresis therapy QW ( weekly ) Q2W ( every 2 week ) least 8 week prior screen visit 1 . Homozygous FH ( familial hypercholesterolemia ) 2 . Background medical LMT ( lipidmodifying therapy ) ( applicable ) stable least 8 week prior screen visit 3 . LDL apheresis schedule/ apheresis setting stable least 8 week prior screen visit 4 . An LDL apheresis schedule QW Q2W 5 . Initiation new exercise program exercise remain stable within 8 week prior screen visit ( week 2 ) 6 . Initiation new diet diet stable within 8 week prior screen visit ( week 2 ) 7 . Use nutraceuticals overthecounter therapy know affect lipid , dose/amount stable least 8 week prior screen visit ( week 2 ) , screen randomization visit 8 . Presence clinically significant uncontrolled endocrine disease know influence serum lipid lipoproteins 9 . Known history positive test human immunodeficiency virus 10 . Use active investigational drug within 1 month 5 halflives screen , whichever longer 11 . Patients treat least 1 dose alirocumab antiPCSK9 monoclonal antibody clinical study 12 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>